TRPH-222 is under clinical development by Triphase Accelerator and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRPH-222’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRPH-222 overview
TRPH-222 is under development for the treatment of relapsed and refractory B-Cell lymphoma including lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, acute lymphoblastic leukemia and mantle cell lymphoma. The therapeutic candidate is a modified humanized antibody conjugated to maytansine payload using Hydrazino-Pictet-Spengler (HIPS) chemistry and 4AP linker. It is administered through intravenous route. It targets cells expressing CD22 and is developed based on SMARTag technology.
Triphase Accelerator overview
Triphase Accelerator is a drug development company providing novel compounds for the treatment of cancer. The company’s pipeline products comprise marizomib, a brain-penetrant proteasome inhibitor, which is developed in both intravenous and oral formulations for the treatment of Glioblastoma; TRPH-222, a novel site-specific antibody-drug conjugate in development for lymphona; and TRPH-395 a novel small molecule inhibitor that disrupts WDR5 protein-protein interactions in solid tumors and hematological cancers. Triphase Accelerator is active in licensing oncology products of biotechnology, various educational institutions, and pharmaceutical companies. The company seeks to work in partnership with other companies and research institutions to advance its oncology drug candidates. The company has operations in Canada and the US. Triphase Accelerator is headquartered in Toronto, Ontario, Canada.
For a complete picture of TRPH-222’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
